Indivior Pharmaceuticals Inc
Indivior Pharmaceuticals Inc Fundamental Analysis
Indivior Pharmaceuticals Inc (INDV) shows moderate financial fundamentals with a PE ratio of 18.68, profit margin of 16.94%, and ROE of -98.94%. The company generates $1.2B in annual revenue with moderate year-over-year growth of 8.69%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -19.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze INDV's fundamental strength across five key dimensions:
Efficiency Score
ExcellentINDV demonstrates superior asset utilization.
Valuation Score
ExcellentINDV trades at attractive valuation levels.
Growth Score
ExcellentINDV delivers strong and consistent growth momentum.
Financial Health Score
ModerateINDV shows balanced financial health with some risks.
Profitability Score
WeakINDV struggles to sustain strong margins.
Key Financial Metrics
Is INDV Expensive or Cheap?
P/E Ratio
INDV trades at 18.68 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, INDV's PEG of 0.66 indicates potential undervaluation.
Price to Book
The market values Indivior Pharmaceuticals Inc at -40.02 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 12.49 times EBITDA. This signals the market has high growth expectations.
How Well Does INDV Make Money?
Net Profit Margin
For every $100 in sales, Indivior Pharmaceuticals Inc keeps $16.94 as profit after all expenses.
Operating Margin
Core operations generate 24.44 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-98.94 in profit for every $100 of shareholder equity.
ROA
Indivior Pharmaceuticals Inc generates $17.44 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Indivior Pharmaceuticals Inc generates limited operating cash flow of $-18.92M, signaling weaker underlying cash strength.
Free Cash Flow
Indivior Pharmaceuticals Inc generates weak or negative free cash flow of $-85.46M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.68 in free cash annually.
FCF Yield
INDV converts -2.18% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
18.68
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.66
vs 25 benchmark
P/B Ratio
Price to book value ratio
-40.02
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.16
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-3.58
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.71
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.99
vs 25 benchmark
ROA
Return on assets percentage
0.17
vs 25 benchmark
ROCE
Return on capital employed
1.04
vs 25 benchmark
How INDV Stacks Against Its Sector Peers
| Metric | INDV Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 18.68 | 28.25 | Better (Cheaper) |
| ROE | -98.94% | 780.00% | Weak |
| Net Margin | 16.94% | -20122.00% (disorted) | Strong |
| Debt/Equity | -3.58 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 0.71 | 4.66 | Weak Liquidity |
| ROA | 17.44% | -14687.00% (disorted) | Strong |
INDV outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Indivior Pharmaceuticals Inc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
61.25%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-98.41%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-74.60%
Industry Style: Defensive, Growth, Innovation
Declining